CN102552410B - 一种治疗高血压疾病药物的制备方法 - Google Patents
一种治疗高血压疾病药物的制备方法 Download PDFInfo
- Publication number
- CN102552410B CN102552410B CN201210011452.0A CN201210011452A CN102552410B CN 102552410 B CN102552410 B CN 102552410B CN 201210011452 A CN201210011452 A CN 201210011452A CN 102552410 B CN102552410 B CN 102552410B
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- crushing
- drying
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 238000001035 drying Methods 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 18
- 241000756943 Codonopsis Species 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 239000009188 angelicae sinensis extract Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000036772 blood pressure Effects 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 7
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- 210000000952 spleen Anatomy 0.000 abstract description 4
- 210000003169 central nervous system Anatomy 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 244000104272 Bidens pilosa Species 0.000 abstract 1
- 235000010662 Bidens pilosa Nutrition 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 230000009897 systematic effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 6
- 229910052753 mercury Inorganic materials 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940124567 diuretic antihypertensive agent Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗高血压疾病药物的制备方法,以重量份计,其特征在于:包括以下组分:当归4~12份,党参4~14份,杜仲4~12份,桑叶8~16份,鬼针草8~16份,绞股蓝8~16份。本发明,具有降血压,降血脂、益气补血,护肝养肾,健脾胃,润肠通便,抑制血小板聚集,抑制中枢神经系统,增加机体免疫力等系统性综合作用,有效率达到95%以上。
Description
技术领域
本发明涉及一种治疗高血压疾病的药物。具体地说是以中草药为原料,采用溶剂提取法提取的有效成分组合而成的药物。
背景技术
高血压是心脑血管疾病的罪魁祸首,是肾及内脏器衰竭死亡的根因,具有发病率高,控制率低的特点。而心脑血管疾病已经取代传染病成为人类健康的头号杀手,是全球范围内的重大公共卫生问题。据统计,全世界高血压患病人数已达6亿,我国2004年居民营养与健康现状调查结果显示,我国18岁及以上居民高血压发病率为18.8%,估计全国患病人数超过1.6亿,预计2025年将达4亿。目前国内外对本病药物治疗,遇到以下棘手问题:一是由于高血压发病机制的复杂性多样性的特征,给高血压药物治疗带来一定的难度;二是降压药物的选用难度,对各种类型不同病期的高血压很难做到几种药物合理搭配治疗;三是选用或联合应用不当,即达不到预期疗效,且有导致其他意外的可能;四是长期服用西药易产生严重的耐药性、依赖性,使重要器官受到伤害。
发明内容
针对以上问题,本发明的目的在于提供一种治疗高血压疾病的药物及其制备方法,是将当归、党参、杜仲、桑叶、鬼针草和绞股蓝分别用乙醇回流提取、干燥,粉碎后按一定比例混合,制成胶囊或片剂。
本发明的技术方案是通过以下方式实现的:一种治疗高血压疾病的药物,以重量份计,包括以下组分:当归4~12份,党参4~14份,杜仲4~12份,桑叶8~16份,鬼针草8~16份,绞股蓝8~16份。
本发明的制备方法是:
1)、当归提取物:取当归的药用部位,干燥后砍片,加70-85%浓度的乙醇,料液比1∶8,温度60-70℃回流提取1-2小时;再加6倍乙醇量,回流提取两次,每次1小时;合并三次提取液,减压浓缩,喷雾干燥,粉碎至80目;
2)、党参提取物:取党参干燥粉碎,加浓度60-70%的乙醇,料液比1∶40,微波加热至60-70℃,回流提取1.5小时,将提取液减压浓缩,干燥粉碎至80目;
3)、杜仲提取物:将杜仲去净外层粗皮,粉碎,加入浓度60-70%的乙醇,料液比1∶12,提取温度60-80℃回流提取3次,每次2小时,将提取液、减压浓缩喷雾干燥,粉碎至80目;
4)、桑叶提取物:取霜后桑叶干燥粉碎,加浓度为60-70%的乙醇,料液比为1∶12,在60-70℃微波条件下,萃取20分钟,提取2次,将提取液减压浓缩,干燥粉碎至80目;
5)、鬼针草提取物:取鬼针草干燥制成粉状,加浓度70-80%的乙醇,料液比1∶14,提取时间0.5小时,提取温度90℃,将提取液减压浓缩,干燥粉碎至80目;
6)、绞股蓝提取物:取绞股蓝干燥粉碎,加浓度为60-75%的乙醇,料液比为1∶10,浸泡12小时,用超声提取3次,每次1.5小时,将提取液减压浓缩,干燥粉碎至80目;
7)、取上述的当归4~12份,党参4~14份,杜仲4~12份,桑叶8~16份,鬼针草8~16份,绞股蓝8~16份混合后,按常规工艺制成胶囊剂或片剂。
本发明,具有降血压,降血脂、益气补血,护肝养肾,健脾胃,润肠通便,抑制血小板聚集,抑制中枢神经系统,增加机体免疫力等系统性综合作用,有效率达到95%以上。
具体实施方式
实施例1:
一种治疗高血压疾病的药物,以重量份计,由以下组分:当归12份,党参6份,杜仲10份,桑叶8份,鬼针草8份,绞股蓝8份。
实施例2:当归4份,党参8份,杜仲4份,桑叶10份,鬼针草8份,绞股蓝15份。
实施例3:当归4份,党参6份,杜仲12份,桑叶14份,鬼针草12份,绞股蓝10份。
本发明的制备方法是:
1、当归提取物:当归提取物:取当归的药用部位,干燥后砍片,加85%浓度的乙醇,料液比1∶8,温度60-70℃回流提取1-2小时;再加6倍乙醇量,回流提取两次,每次1小时;合并三次提取液,减压浓缩,喷雾干燥,粉碎至80目备用。
2、党参提取物:党参提取物:取党参干燥粉碎,加浓度60%的乙醇,料液比1∶40,微波加热至70℃,回流提取1.5小时,将提取液减压浓缩,干燥粉碎至80目。
3、杜仲提取物:将杜仲去净外层粗皮,粉碎,加入浓度65%的乙醇,料液比1∶12,提取温度70℃回流提取3次,每次2小时,将提取液、减压浓缩喷雾干燥,粉碎至80目。
4、桑叶提取物:取霜后桑叶干燥粉碎,加浓度为70%的乙醇,料液比为1∶12,在60℃微波条件下,萃取20分钟,提取2次,将提取液减压浓缩,干燥粉碎至80目。
5、鬼针草提取物:鬼针草提取物:取鬼针草干燥制成粉状,加浓度80%的乙醇,料液比1∶14,提取时间0.5小时,提取温度90℃,将提取液减压浓缩,干燥粉碎至80目。
6、绞股蓝提取物:取绞股蓝干燥粉碎,加浓度为75%的乙醇,料液比为1∶10,浸泡12小时,用超声提取3次,每次80分钟,将提取液减压浓缩,干燥粉碎至80目。
7、取上述的当归4~12份,党参6~8份,杜仲4~12份,桑叶8~16份,鬼针草8~16份,绞股蓝8~16份混合后,按常规工艺制成胶囊剂或片剂。
本发明药物在临床应用上,对60例患有不同类型,不同病史,不同症状,不同年龄性别的高血压患者进行服药治疗观察,95%的患者服药15天后均有不同程度的下降,症状显著改善;服用三个月后做血清检验对比,73%的患者胆固醇(TC)、低密度脂蛋白(LDL-C)、甘油三酯(TG)均达到正常值内,高密度脂蛋白(HDL-C)明显升高;25%的患者(TC)、(LDL-C)、(TG)接近正常值,(HDL-C)也有所升高,而血清指标部分或全部正常的患者也不受任何影响。
本发明药物治疗期为三个月,一个月为疗程,共三个疗程。服用法用量:每日2次,胶囊每次3粒,温水送服。
案例1:患者余某,男62岁,经常后脑感到疼痛,同时伴有恶心作呕现象,多年来吃了不少降压药物,血压始终忽高忽低。经检查,胆固醇6.08(正常参考值2.85-5.60mmol/l),甘油三脂2.21(正常参考值0.49-1.7mmol/l)两项指标都超过正常参考值。服用本发明胶囊三个疗程后,血压平稳回复,症状改善,再次血清检查胆固醇降至5.11mmol/l恢复正常,甘油三脂降至1.79mmol/l,显著下降,接近正常。
案例2:患者叶某,男44岁,整天头脑昏昏沉沉,腿脚没劲,一到上午9点总要睡上一会才能清醒。血压总在收缩压165-170毫米汞柱,舒展压100-115毫米汞柱之间,自从开始服本发明胶囊一周后,自觉头不那么晕了,腿也有力气了,血压稳步下降,坚持服用三个月后,症状完全消失,血压回复到收缩压140毫米汞柱,舒展压77毫米汞柱。
案例3:患者王某,男73岁,高血压多年,头晕心慌,目涩耳鸣,无法入睡,走路不稳,血压总在165-190和110-120毫米汞柱之间,服用本发明胶囊一个疗程后症状有明显改善,能入睡,心不慌,继续服三个疗程后,血压基本能稳定在145-150/80-85毫米汞柱之间,精神也好多了。
本发明药物原料提取物降低血压的药理作用:
1、当归提取物:能使心肌毛细血管开放增多,心肌营养性血流量增加,对心肌缺血有明显保护作用;促进造血、活血作用;扩张血管、降低血脂,抗动脉粥样硬化作用;多种活性成分综合作用能抑制血小板聚集,降低血浆粘滞性,起到抗血栓作用;对肝损伤有保护作用,并能促进肝细胞再生和恢复肝脏某些功能的作用;对中枢神经系统有广泛的抑制作用。
2、党参提取物:增强造血功能、有增强心肌收缩力,增加心输出量,抗休克作用;抗常压缺氧,组织细胞缺氧和微循环缺氧;能较好地改善心肌的舒张功能,增加心肌的顺应性,使冠状动脉灌注阻力减少,有利于左心室心肌的血流供应,改善心肌缺血;有扩张外周血管;可明显降低全血比黏度和血浆比动度,抑制血栓形成,并可降低高脂血症血清的低密度脂蛋白,甘油三脂和胆固醇的含量;有抑制血小板聚集、调整胃肠运动功能。
3、杜仲提取物:作为一种自由基清除剂及抗氧化剂,对心血管系统产生保护作用;有增高白血球,保肝护肾利胆和利尿降压作用。
4、桑叶提取物:增加心的收缩力与输出量,并减少心率,扩张冠状血管,改善心肌循环,促进脑组织的新陈代谢和恢复脑细胞功能,改善脑部血液流动,增强血管紧张素转换酶I的活性,促使血压下降;强化毛细血管,降低血液黏度,软化血管,清除体内过氧化物,预防心肌梗死和脑溢血;利尿、通便、减肥。
5、鬼针草提取物:清理血管内膜的脂质沉积,保护血管内皮;降低胆固醇,低密度脂蛋白,甘油三脂改善异常的血流变作用;对肝细胞有保护作用;有活血的功能。
6、绞股蓝提取物:降血脂、血压,增加冠状动脉和脑血流量,防治动脉硬化;有健脾胃,护肝,改善肾功能和消除激素类药物的毒副作用。
本发明,提取物中各个所含的不同成分,配比组合的,不同成分含不同类型的降压机制,协同作用,药效互补,从而通过不同途径发挥更大的作用。运用系统工程治疗手段,不但有效降压降脂,还能益气补血,强心肌,补肝肾,健脾胃,润肠通便,从根本上消除引起血压高的各种因素,达到治病强身的终极目标。该药剂在提取和配伍过程中不添加任何西药成分和其他化学成分,纯植物提取物所制,服用后血压平稳下降,症状逐步消失,没有任何毒副作用。该药剂采用提取物所制,体积小,含量高,服用剂量少,送服方便。
Claims (1)
1.一种治疗高血压疾病药物的制备方法,其特征在于:包括以下步骤:
1)、当归提取物:取当归的药用部位,干燥后砍片,加70-85%浓度的乙醇,料液比1∶8,温度60-70℃回流提取1-2小时;再加6倍乙醇量,回流提取两次,每次1小时;合并三次提取液,减压浓缩,喷雾干燥,粉碎至80目;
2)、党参提取物:取党参干燥粉碎,加浓度60-70%的乙醇,料液比1∶40,微波加热至60-70℃,回流提取1.5小时,将提取液减压浓缩,干燥粉碎至80目;
3)、杜仲提取物:将杜仲去净外层粗皮,粉碎,加入浓度60-70%的乙醇,料液比1∶12,提取温度60-80℃回流提取3次,每次2小时,将提取液、减压浓缩喷雾干燥,粉碎至80目;
4)、桑叶提取物:取霜后桑叶干燥粉碎,加浓度为60-70%的乙醇,料液比为1∶12,在60-70℃微波条件下,萃取20分钟,提取2次,将提取液减压浓缩,干燥粉碎至80目;
5)、鬼针草提取物:取鬼针草干燥制成粉状,加浓度70-80%的乙醇,料液比1∶14,提取时间0.5小时,提取温度90℃,将提取液减压浓缩,干燥粉碎至80目;
6)、绞股蓝提取物:取绞股蓝干燥粉碎,加浓度为60-75%的乙醇,料液比为1∶10,浸泡12小时,用超声提取3次,每次1.5小时,将提取液减压浓缩,干燥粉碎至80目;
7)、取上述的当归提取物4~12份,党参提取物4~14份,杜仲提取物4~12份,桑叶提取物8~16份,鬼针草提取物8~16份,绞股蓝提取物8~16份混合后,按常规工艺制成胶囊剂或片剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210011452.0A CN102552410B (zh) | 2012-01-16 | 2012-01-16 | 一种治疗高血压疾病药物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210011452.0A CN102552410B (zh) | 2012-01-16 | 2012-01-16 | 一种治疗高血压疾病药物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102552410A CN102552410A (zh) | 2012-07-11 |
CN102552410B true CN102552410B (zh) | 2014-01-22 |
Family
ID=46399866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210011452.0A Expired - Fee Related CN102552410B (zh) | 2012-01-16 | 2012-01-16 | 一种治疗高血压疾病药物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102552410B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104083471A (zh) * | 2013-04-01 | 2014-10-08 | 李永君 | 一种治疗高血压的口服液 |
CN109275751A (zh) * | 2017-07-20 | 2019-01-29 | 张家界茶坤缘生物科技开发有限公司 | 杜仲叶降压茶及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1081826A (zh) * | 1993-05-31 | 1994-02-16 | 赵岁元 | 秦宝健身茶 |
KR100572621B1 (ko) * | 2003-03-19 | 2006-04-24 | 한국 한의학 연구원 | 비만 및 성인병 치료용 조성물 |
KR100814382B1 (ko) * | 2006-08-03 | 2008-03-18 | 한국식품연구원 | 기능성 더덕 음료 및 그의 제조방법 |
CN101138374B (zh) * | 2007-10-18 | 2010-05-19 | 蔡旻君 | 一种杜仲茶颗粒及其制备方法 |
CN101595927A (zh) * | 2008-06-06 | 2009-12-09 | 刘泳宏 | 一种天然养脏降脂、降糖、降压茶及制作方法 |
JP5835867B2 (ja) * | 2009-09-30 | 2015-12-24 | 小林製薬株式会社 | 経口組成物 |
-
2012
- 2012-01-16 CN CN201210011452.0A patent/CN102552410B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102552410A (zh) | 2012-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102159227B (zh) | 净化血管的药物组合物及其制备方法 | |
CN101168021B (zh) | 治疗心脑疾病的药物 | |
CN102772704A (zh) | 老年病药物 | |
CN103623146B (zh) | 能够促进人体微循环的沐浴药酒 | |
CN102225100A (zh) | 一种治疗心脑血管疾病的中药配方及其产品制备工艺 | |
CN102210835B (zh) | 治疗冠心病的中药 | |
CN104173458B (zh) | 一种具有防治高尿酸血症作用的中药组合物及其制备方法 | |
CN102552410B (zh) | 一种治疗高血压疾病药物的制备方法 | |
CN102161960B (zh) | 一种美容调节酒 | |
CN104083438A (zh) | 一种缓解高血压的苦瓜中药制剂及制备方法 | |
CN103830436A (zh) | 治疗高血压的中药组合物及其制备方法 | |
CN105267889A (zh) | 一种治疗高血脂的中药制剂 | |
CN106938048A (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN100355434C (zh) | 一种防治心脑血管疾病的药物 | |
CN105617198A (zh) | 治疗风寒腰痛的药酒的制备方法 | |
CN104721092A (zh) | 一种含银杏叶水提剂的沐浴液及其制备方法 | |
CN104258034A (zh) | 一种增强免疫力的中药组合物 | |
CN1279951C (zh) | 治疗甲亢及单纯性甲状腺肿大纯中药胶囊 | |
CN103549072A (zh) | 一种益气护脑茶及其制备方法 | |
CN102755444A (zh) | 一种用于治疗高血脂症的中药组合物及其制备方法 | |
CN102008665A (zh) | 治疗盗汗症的中药 | |
CN105832934A (zh) | 一种治疗高血压病的中药 | |
CN105663224A (zh) | 一种用于治疗心脑血管疾病的组合物及其制剂 | |
CN104305186B (zh) | 一种具有降血压功效的食品、保健品或药物组合物 | |
CN105395864A (zh) | 一种治疗失眠的泡脚粉 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Li Yongjun Document name: Notification to Go Through Formalities of Registration |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Li Yongjun Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice |
Addressee: Li Yongjun Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140122 Termination date: 20190116 |
|
CF01 | Termination of patent right due to non-payment of annual fee |